文献速递肝病

iRhom2通过激活MAP3K7依赖通路促进肝脏脂肪变性

iRhom2 Promotes Hepatic Steatosis by Activating MAP3K7-Dependent Pathway.
PubMed 文献 · Hepatology · 2021-01-01

研究在高脂饮食小鼠模型中探讨iRhom2调控炎症促进非酒精性脂肪性肝病进展的机制。iRhom2缺失小鼠胰岛素抵抗、肝脏脂肪变性和巨噬细胞炎症激活显著减轻,而iRhom2过表达小鼠加重;机制上iRhom2与MAP3K7结合促进其磷酸化及NF-κB级联激活,进而激活JNK/IRS1信号并干扰AKT/GSK3β胰岛素信号。

要点

  • iRhom2缺失小鼠高脂饮食下肝脏脂肪变性和胰岛素抵抗显著减轻。
  • iRhom2过表达小鼠高脂饮食下肝脏脂肪变性和胰岛素抵抗加重。
  • iRhom2/MAP3K7轴是iRhom2调控肝脏脂肪变性的关键通路。

核心结论

  • iRhom2可能成为治疗高脂饮食诱导的肝脏脂肪变性和胰岛素抵抗的治疗靶点。

研究设计与样本

  • 研究采用iRhom2基因敲除小鼠、iRhom2过表达小鼠及髓系细胞特异性iRhom2缺失小鼠,给予高脂饮食干预,并进行骨髓移植实验。

主要发现

  • iRhom2缺陷(敲除)小鼠的胰岛素抵抗、肝脏脂肪变性和特定巨噬细胞炎症激活显著减轻,而iRhom2过表达小鼠上述指标加重。
  • 高脂饮食下,iRhom2敲除小鼠及髓系细胞特异性iRhom2缺失小鼠的肝脏脂肪变性和胰岛素抵抗均较对照组轻。
  • 将健康小鼠骨髓细胞移植入iRhom2敲除小鼠后,胰岛素抵抗和肝脏脂质异常加重。
  • 高脂饮食下肝脏iRhom2与MAP3K7结合,促进MAP3K7磷酸化和NF-κB级联激活,进而激活JNK/IRS1信号并干扰AKT/GSK3β相关胰岛素信号。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) has been widely recognized as a precursor to metabolic complications. Elevated inflammation levels are predictive of NAFLD-associated metabolic disorder. Inactive rhomboid-like protein 2 (iRhom2) is regarded as a key regulator in inflammation. However, the precise mechanisms by which iRhom2-regulated inflammation promotes NAFLD progression remain to be elucidated. APPROACH AND RESULTS: Here, we report that insulin resistance, hepatic steatosis, and specific macrophage inflammatory activation are significantly alleviated in iRhom2-deficient (knockout [KO]) mice, but aggravated in iRhom2 overexpressing mice. We further show that, mechanistically, in response to a high-fat diet (HFD), iRhom2 KO mice and mice with iRhom2 deficiency in myeloid cells only showed less severe hepatic steatosis and insulin resistance than controls. Inversely, transplantation of bone marrow cells from healthy mice to iRhom2 KO mice expedited the severity of insulin resistance and hepatic dyslipidemia. Of note, in response to HFD, hepatic iRhom2 binds to mitogen-activated protein kinase kinase kinase 7 (MAP3K7) to facilitate MAP3K7 phosphorylation and nuclear factor kappa B cascade activation, thereby promoting the activation of c-Jun N-terminal kinase/insulin receptor substrate 1 signaling, but disturbing AKT/glycogen synthase kinase 3β-associated insulin signaling. The iRhom2/MAP3K7 axis is essential for iRhom2-regulated liver steatosis. CONCLUSIONS: iRhom2 may represent a therapeutic target for the treatment of HFD-induced hepatic steatosis and insulin resistance.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Xu M, Ge C, Zhu L, et al. iRhom2 Promotes Hepatic Steatosis by Activating MAP3K7-Dependent Pathway. Hepatology. 2021. PMID: 32592194. doi:10.1002/hep.31436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。